Bioprocessing - Upstream & Downstream

Sitting Down With … Piper Trelstad, Head of CMC, The Bill & Melinda Gates Medical Research Institute

Experts from Lonza share how biologics and CGT can recognize the gaps and similarities that can be utilized to optimize cell culture media challenges.

From developments in cell culture media to enhancing the potency of monoclonal antibodies – check out our free eBook.

The analytical complexities that come with oligonucleotide manufacturing are difficult, but not impossible.

Here’s how an mRNA-based approach can overcome the development challenges of designing protein therapeutics.

Four approaches to address the challenge of producing complex therapeutics in standard cell lines.

Who deserves a place on our annual list of inspirational and influential industry professionals?

An expert from Samsung Biologics offers her perspective on the future of antibody drug conjugates.

NervGen President and CEO Mike Kelly discusses the potential of the company’s investigational drug NVG-291 for spinal cord injury.

How metabolic conditioning could improve cell therapy potency and persistence.